Eupraxia Pharmaceuticals Inc.
EPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001581178
No open-market purchases or sales by Eupraxia Pharmaceuticals Inc. insiders were filed in the last 90 days; 67 institutions reported holding it in 13F filings for Q2 2026, worth $163.6M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Eupraxia Pharmaceuticals Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +13 vs. Q2 2025
- Shares held
- 12.8M
- +10.8M (+550.4%) vs. Q2 2025
- Total value
- $75.3M
- +$64.4M (+591.4%) vs. Q2 2025
- New holders
- 15
- 7 more added
- Sold out
- 2
- 2 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EPRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 67 | $163.6M |
| Q1 2026 | 55 | $160.3M |
| Q4 2025 | 36 | $105.1M |
| Q3 2025 | 27 | $75.3M |
| Q2 2025 | 14 | $10.9M |
| Q1 2025 | 11 | $7.09M |
| Q4 2024 | 9 | $5.63M |
| Q3 2024 | 8 | $4.55M |
| Q2 2024 | 8 | $4.43M |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Eupraxia Pharmaceuticals Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 4,058,899 | $23.9M | 0.14% | +4,058,899 | New |
| Balyasny Asset Management LLC | 1,350,000 | $7.96M | 0.02% | +1,350,000 | New |
| Vivo Capital, LLC | 1,350,000 | $7.96M | 0.64% | +1,350,000 | New |
| Scotia Capital Inc. | 1,277,885 | $7.25M | 0.03% | −14,104−1.1% | Reduced |
| Great Point Partners LLC | 1,200,000 | $7.08M | 2.96% | +1,200,000 | New |
| Ally Bridge Group (NY) LLC | 915,000 | $5.40M | 4.52% | +915,000 | New |
| Logos Global Management LP | 900,000 | $5.31M | 0.52% | +900,000 | New |
| Royal Bank of Canada | 428,804 | $2.53M | 0.00% | +220+0.1% | Added |
| Velan Capital Investment Management LP | 352,000 | $2.08M | 1.95% | +352,000 | New |
| Affinity Asset Advisors, LLC | 300,000 | $1.77M | 0.16% | +300,000 | New |
| Alyeska Investment Group, L.P. | 250,000 | $1.48M | 0.00% | +250,000 | New |
| UBS Group AG | 95,756 | $565.0K | 0.00% | +58,257+155.4% | Added |
| Ingalls & Snyder LLC | 59,100 | $349.0K | 0.01% | +21,900+58.9% | Added |
| Bank of America Corp | 45,577 | $268.9K | 0.00% | +33,018+262.9% | Added |
| Goldman Sachs Group Inc | 40,100 | $236.6K | 0.00% | +300+0.8% | Added |
| Bank of Montreal | 37,250 | $219.4K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 33,373 | $196.9K | 0.00% | +21,161+173.3% | Added |
| Guardian Partners Inc. | 24,130 | $147.4K | 0.01% | +24,130 | New |
| Acadian Asset Management LLC | 21,400 | $125.0K | 0.00% | +21,400 | New |
| JPMorgan Chase & Co | 16,467 | $97.2K | 0.00% | −2,250−12.0% | Reduced |
| CIBC World Markets Inc. | 15,000 | $88.4K | 0.00% | 00.0% | Unchanged |
| Integrated Wealth Concepts LLC | 12,000 | $70.8K | 0.00% | +12,000 | New |
| TCI Wealth Advisors, Inc. | 11,000 | $64.9K | 0.00% | +11,000 | New |
| TD Waterhouse Canada Inc. | 9,600 | $56.2K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 9,091 | $51.6K | 0.00% | +9,091 | New |
| National Bank of Canada | 882 | $5.03K | 0.00% | +152+20.8% | Added |
| Tower Research Capital LLC (TRC) | 9 | $53 | 0.00% | +9 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −18,236−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −10,700−100.0% | Sold out |